Author:
Chen Yu,Pei Yanqing,Luo Jingyu,Huang Zhaoqin,Yu Jinming,Meng Xiangjiao
Funder
National Natural Science Foundation of China
Natural Science Foundation of Shandong Province
Subject
Immunology,Immunology and Allergy
Reference97 articles.
1. The PD1:PD-L1/2 pathway from discovery to clinical implementation;Bardhan;Front Immunol.,2016
2. Treatment of relapsed or refractory classical hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study;Song;Leukemia.,2020
3. Safety and activity of sintilimab in patients with relapsed or refractory classical hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial;Shi;Lancet Haematol.,2019
4. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody;Fu;Acta Pharmacol Sin.,2017
5. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol.,2008
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献